NASDAQ:ORPH

Orphazyme A/S Competitors

$5.97

-0.55 (-8.44 %)

(As of 06/22/2021 12:00 AM ET)

Add

Compare

Today's Range

$5.84

▼

$6.34

50-Day Range

$4.82

▼

$21.00

52-Week Range

$4.75

▼

$77.77

Volume8.88 million shs

Average Volume4.01 million shs

Market Capitalization$208.66 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Orphazyme A/S (NASDAQ:ORPH) Vs. MRUS, COLL, AFMD, KPTI, SLN, and CRNX

Should you be buying ORPH stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Orphazyme A/S, including Merus (MRUS), Collegium Pharmaceutical (COLL), Affimed (AFMD), Karyopharm Therapeutics (KPTI), Silence Therapeutics (SLN), and Crinetics Pharmaceuticals (CRNX).

Orphazyme A/S vs. Merus Stock

Merus (NASDAQ:MRUS) and Orphazyme A/S (NASDAQ:ORPH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Analyst Ratings

This is a summary of current recommendations for Merus and Orphazyme A/S, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Merus	0	1	5	0	2.83
Orphazyme A/S	2	1	0	0	1.33

Merus presently has a consensus price target of $29.40, indicating a potential upside of 35.17%. Orphazyme A/S has a consensus price target of $16.00, indicating a potential upside of 168.01%. Given Orphazyme A/S's higher possible upside, analysts plainly believe Orphazyme A/S is more favorable than Merus.

Profitability

This table compares Merus and Orphazyme A/S's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Merus	-248.38%	-57.90%	-28.43%
Orphazyme A/S	N/A	N/A	N/A

Valuation and Earnings

This table compares Merus and Orphazyme A/S's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Merus	$29.94 million	27.86	$-85,510,000.00	($2.60)	-8.37
Orphazyme A/S	N/A	N/A	$-97,010,000.00	($3.42)	-1.75

Merus has higher revenue and earnings than Orphazyme A/S. Merus is trading at a lower price-to-earnings ratio than Orphazyme A/S, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

69.7% of Merus shares are owned by institutional investors. Comparatively, 0.8% of Orphazyme A/S shares are owned by institutional investors. 2.9% of Merus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Merus beats Orphazyme A/S on 7 of the 12 factors compared between the two stocks.

Orphazyme A/S vs. Collegium Pharmaceutical Stock

Collegium Pharmaceutical (NASDAQ:COLL) and Orphazyme A/S (NASDAQ:ORPH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Analyst Ratings

This is a summary of current recommendations for Collegium Pharmaceutical and Orphazyme A/S, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	1	0	2	0	2.33
Orphazyme A/S	2	1	0	0	1.33

Collegium Pharmaceutical presently has a consensus price target of $25.00, indicating a potential upside of 8.60%. Orphazyme A/S has a consensus price target of $16.00, indicating a potential upside of 168.01%. Given Orphazyme A/S's higher possible upside, analysts plainly believe Orphazyme A/S is more favorable than Collegium Pharmaceutical.

Profitability

This table compares Collegium Pharmaceutical and Orphazyme A/S's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	13.06%	24.52%	6.50%
Orphazyme A/S	N/A	N/A	N/A

Valuation and Earnings

This table compares Collegium Pharmaceutical and Orphazyme A/S's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$310.02 million	2.62	$26.75 million	$0.76	30.29
Orphazyme A/S	N/A	N/A	$-97,010,000.00	($3.42)	-1.75

Collegium Pharmaceutical has higher revenue and earnings than Orphazyme A/S. Orphazyme A/S is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

0.8% of Orphazyme A/S shares are owned by institutional investors. 5.2% of Collegium Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Collegium Pharmaceutical beats Orphazyme A/S on 10 of the 12 factors compared between the two stocks.

Orphazyme A/S vs. Affimed Stock

Affimed (NASDAQ:AFMD) and Orphazyme A/S (NASDAQ:ORPH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Profitability

This table compares Affimed and Orphazyme A/S's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Affimed	-144.10%	-87.56%	-34.72%
Orphazyme A/S	N/A	N/A	N/A

Insider and Institutional Ownership

79.7% of Affimed shares are owned by institutional investors. Comparatively, 0.8% of Orphazyme A/S shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Affimed and Orphazyme A/S's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Affimed	$32.39 million	25.00	$-47,250,000.00	($0.57)	-14.46
Orphazyme A/S	N/A	N/A	$-97,010,000.00	($3.42)	-1.75

Affimed has higher revenue and earnings than Orphazyme A/S. Affimed is trading at a lower price-to-earnings ratio than Orphazyme A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for Affimed and Orphazyme A/S, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Affimed	0	0	5	0	3.00
Orphazyme A/S	2	1	0	0	1.33

Affimed presently has a consensus price target of $13.80, indicating a potential upside of 67.48%. Orphazyme A/S has a consensus price target of $16.00, indicating a potential upside of 168.01%. Given Orphazyme A/S's higher possible upside, analysts plainly believe Orphazyme A/S is more favorable than Affimed.

Summary

Affimed beats Orphazyme A/S on 6 of the 11 factors compared between the two stocks.

Orphazyme A/S vs. Karyopharm Therapeutics Stock

Karyopharm Therapeutics (NASDAQ:KPTI) and Orphazyme A/S (NASDAQ:ORPH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Profitability

This table compares Karyopharm Therapeutics and Orphazyme A/S's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-177.34%	-357.73%	-61.51%
Orphazyme A/S	N/A	N/A	N/A

Institutional and Insider Ownership

80.1% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 0.8% of Orphazyme A/S shares are owned by institutional investors. 10.2% of Karyopharm Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Karyopharm Therapeutics and Orphazyme A/S's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$108.08 million	7.25	$-196,270,000.00	($2.72)	-3.83
Orphazyme A/S	N/A	N/A	$-97,010,000.00	($3.42)	-1.75

Orphazyme A/S has lower revenue, but higher earnings than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than Orphazyme A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Karyopharm Therapeutics and Orphazyme A/S, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	0	1	7	0	2.88
Orphazyme A/S	2	1	0	0	1.33

Karyopharm Therapeutics currently has a consensus target price of $27.75, indicating a potential upside of 166.06%. Orphazyme A/S has a consensus target price of $16.00, indicating a potential upside of 168.01%. Given Orphazyme A/S's higher possible upside, analysts clearly believe Orphazyme A/S is more favorable than Karyopharm Therapeutics.

Orphazyme A/S vs. Silence Therapeutics Stock

Silence Therapeutics (NASDAQ:SLN) and Orphazyme A/S (NASDAQ:ORPH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Profitability

This table compares Silence Therapeutics and Orphazyme A/S's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	N/A	N/A	N/A
Orphazyme A/S	N/A	N/A	N/A

Institutional and Insider Ownership

8.6% of Silence Therapeutics shares are owned by institutional investors. Comparatively, 0.8% of Orphazyme A/S shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Silence Therapeutics and Orphazyme A/S's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$5.48 million	140.92	$-41,790,000.00	($0.40)	-64.80
Orphazyme A/S	N/A	N/A	$-97,010,000.00	($3.42)	-1.75

Silence Therapeutics has higher revenue and earnings than Orphazyme A/S. Silence Therapeutics is trading at a lower price-to-earnings ratio than Orphazyme A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Silence Therapeutics and Orphazyme A/S, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	0	0	2	0	3.00
Orphazyme A/S	2	1	0	0	1.33

Orphazyme A/S has a consensus target price of $16.00, indicating a potential upside of 168.01%. Given Orphazyme A/S's higher possible upside, analysts clearly believe Orphazyme A/S is more favorable than Silence Therapeutics.

Summary

Silence Therapeutics beats Orphazyme A/S on 6 of the 8 factors compared between the two stocks.

Orphazyme A/S vs. Crinetics Pharmaceuticals Stock

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Orphazyme A/S (NASDAQ:ORPH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Profitability

This table compares Crinetics Pharmaceuticals and Orphazyme A/S's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	N/A	-44.81%	-41.52%
Orphazyme A/S	N/A	N/A	N/A

Institutional and Insider Ownership

81.6% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.8% of Orphazyme A/S shares are owned by institutional investors. 7.4% of Crinetics Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Crinetics Pharmaceuticals and Orphazyme A/S's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$70,000.00	10,864.38	$-73,810,000.00	($2.42)	-8.36
Orphazyme A/S	N/A	N/A	$-97,010,000.00	($3.42)	-1.75

Crinetics Pharmaceuticals has higher revenue and earnings than Orphazyme A/S. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Orphazyme A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Crinetics Pharmaceuticals and Orphazyme A/S, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	0	0	5	0	3.00
Orphazyme A/S	2	1	0	0	1.33

Crinetics Pharmaceuticals currently has a consensus target price of $36.25, indicating a potential upside of 79.19%. Orphazyme A/S has a consensus target price of $16.00, indicating a potential upside of 168.01%. Given Orphazyme A/S's higher possible upside, analysts clearly believe Orphazyme A/S is more favorable than Crinetics Pharmaceuticals.

Summary

Crinetics Pharmaceuticals beats Orphazyme A/S on 7 of the 11 factors compared between the two stocks.

Ad All Marijuana Stocks

Seattle Cannabis Blockbuster Set to Double Sales in Next 2 Years!

Thanks to a recent reorganization, acquisitions, and strategic partnerships, one Seattle cannabis blockbuster is poised for a massive expansion in the coming 24 months. With plans to double its annual sales in the next two years, this company’s shares could potentially skyrocket in value.